Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by P. Ruffo
Pcn174 - Nepa, an Oral Fixed Combination of Netupitant and Palonosetron, Is a Cost-Effective Intervention for the Prevention of Chemotherapy-Induced Nausea and Vomiting (Cinv) in Germany and Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn249 - Chemotherapy-Induced Nausea and Vomiting (Cinv) and Drivers of Antiemetic Prescribing: Results of a Qualitative In-Practice Study of Clinicians From Various Settings
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Preventing Chemotherapy-Induced Nausea and Vomiting With Netupitant/Palonosetron, the First Fixed Combination Antiemetic: Current and Future Perspective
Future Oncology
Medicine
Cancer Research
Oncology
Fixed Combination of Oral NEPA (Netupitant‐palonosetron) for the Prevention of Acute and Delayed Chemotherapy‐induced Nausea and Vomiting in Patients Receiving Multiple Cycles of Chemotherapy: Efficacy Data From 2 Randomized, Double‐blind Phase III Studies
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: Approval and Efficacy
Cancer Management and Research
Oncology
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program
Oncologist
Cancer Research
Medicine
Oncology
Ramosetron Versus Palonosetron in Combination With Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Cancer Research and Treatment
Cancer Research
Oncology
Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting
Malignant tumours
Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous Leukemia
Cancer
Cancer Research
Oncology
Palonosetron (Aloxi): A Second-Generation 5-Ht3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting
Baylor University Medical Center Proceedings
Medicine
Pcn298 - Management of Antiemetic Treatment for Chemotherapy-Induced Nausea and Vomiting (Cinv): Patients’, Oncologists’ and Nurses’ Perspectives
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
